These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 19270508)

  • 1. Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed.
    Di Gennaro E; Bruzzese F; Pepe S; Leone A; Delrio P; Subbarayan PR; Avallone A; Budillon A
    Cancer Biol Ther; 2009 May; 8(9):782-91. PubMed ID: 19270508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic antitumour effect of raltitrexed and 5-fluorouracil plus folinic acid combination in human cancer cells.
    Avallone A; Di Gennaro E; Bruzzese F; Laus G; Delrio P; Caraglia M; Pepe S; Comella P; Budillon A
    Anticancer Drugs; 2007 Aug; 18(7):781-91. PubMed ID: 17581300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21(waf1/cip1) expression.
    Noro R; Miyanaga A; Minegishi Y; Okano T; Seike M; Soeno C; Kataoka K; Matsuda K; Yoshimura A; Gemma A
    Cancer Sci; 2010 Jun; 101(6):1424-30. PubMed ID: 20384633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
    Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
    J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models.
    Morelli MP; Tentler JJ; Kulikowski GN; Tan AC; Bradshaw-Pierce EL; Pitts TM; Brown AM; Nallapareddy S; Arcaroli JJ; Serkova NJ; Hidalgo M; Ciardiello F; Eckhardt SG
    Clin Cancer Res; 2012 Feb; 18(4):1051-62. PubMed ID: 22173548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer.
    Alzoubi S; Brody L; Rahman S; Mahul-Mellier AL; Mercado N; Ito K; El-Bahrawy M; Silver A; Boobis A; Bell JD; Hajji N
    Oncotarget; 2016 Jul; 7(28):44505-44521. PubMed ID: 27283986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism.
    Peters GJ; Backus HH; Freemantle S; van Triest B; Codacci-Pisanelli G; van der Wilt CL; Smid K; Lunec J; Calvert AH; Marsh S; McLeod HL; Bloemena E; Meijer S; Jansen G; van Groeningen CJ; Pinedo HM
    Biochim Biophys Acta; 2002 Jul; 1587(2-3):194-205. PubMed ID: 12084461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors.
    van der Wilt CL; Backus HH; Smid K; Comijn L; Veerman G; Wouters D; Voorn DA; Priest DG; Bunni MA; Mitchell F; Jackman AL; Jansen G; Peters GJ
    Cancer Res; 2001 May; 61(9):3675-81. PubMed ID: 11325838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase.
    Di Gennaro E; Piro G; Chianese MI; Franco R; Di Cintio A; Moccia T; Luciano A; de Ruggiero I; Bruzzese F; Avallone A; Arra C; Budillon A
    Br J Cancer; 2010 Nov; 103(11):1680-91. PubMed ID: 21045833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT.
    Bruzzese F; Leone A; Rocco M; Carbone C; Piro G; Caraglia M; Di Gennaro E; Budillon A
    J Cell Physiol; 2011 Sep; 226(9):2378-90. PubMed ID: 21660961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiproliferative effects of ZD0473 (AMD473) in combination with 5-fluorouracil or SN38 in human colorectal cancer cell lines.
    Plasencia C; Abad A; Martinez-Balibrea E; Taron M
    Invest New Drugs; 2004 Nov; 22(4):399-409. PubMed ID: 15292710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Costs incurred by patients undergoing advanced colorectal cancer therapy. A comparison of raltitrexed and fluorouracil plus folinic acid.
    Sculpher M; Palmer MK; Heyes A
    Pharmacoeconomics; 2000 Apr; 17(4):361-70. PubMed ID: 10947491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vorinostat Potentiates 5-Fluorouracil/Cisplatin Combination by Inhibiting Chemotherapy-Induced EGFR Nuclear Translocation and Increasing Cisplatin Uptake.
    Piro G; Roca MS; Bruzzese F; Carbone C; Iannelli F; Leone A; Volpe MG; Budillon A; Di Gennaro E
    Mol Cancer Ther; 2019 Aug; 18(8):1405-1417. PubMed ID: 31189612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arsenic trioxide suppresses thymidylate synthase in 5-FU-resistant colorectal cancer cell line HT29 In Vitro re-sensitizing cells to 5-FU.
    Subbarayan PR; Lee K; Ardalan B
    Anticancer Res; 2010 Apr; 30(4):1157-62. PubMed ID: 20530422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination studies of antifolates with 5-fluorouracil in colon cancer cell lines.
    van der Wilt CL; Kuiper CM; Peters GJ
    Oncol Res; 1999; 11(8):383-91. PubMed ID: 10803742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels.
    Kretzner L; Scuto A; Dino PM; Kowolik CM; Wu J; Ventura P; Jove R; Forman SJ; Yen Y; Kirschbaum MH
    Cancer Res; 2011 Jun; 71(11):3912-20. PubMed ID: 21502403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis.
    Bruzzese F; Rocco M; Castelli S; Di Gennaro E; Desideri A; Budillon A
    Mol Cancer Ther; 2009 Nov; 8(11):3075-87. PubMed ID: 19887547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.
    Carbone C; Di Gennaro E; Piro G; Milone MR; Pucci B; Caraglia M; Budillon A
    Amino Acids; 2017 Mar; 49(3):517-528. PubMed ID: 27761756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HSP90 inhibition downregulates thymidylate synthase and sensitizes colorectal cancer cell lines to the effect of 5FU-based chemotherapy.
    Nagaraju GP; Alese OB; Landry J; Diaz R; El-Rayes BF
    Oncotarget; 2014 Oct; 5(20):9980-91. PubMed ID: 25296971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative cytotoxicity of folate-based inhibitors of thymidylate synthase and 5-fluorouracil +/- leucovorin in MGH-U1 cells.
    Erlichman C; Mitrovski B
    Cancer Chemother Pharmacol; 1994; 34(1):51-6. PubMed ID: 8174202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.